Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

Cartesian Therapeutics, Inc. announced that it received FDA agreement on the design of its upcoming Phase 3 AURORA trial for Descartes-08, an mRNA cell therapy intended for treating myasthenia ...

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 25.1% of Lyell Immunopharma ...

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company, on Monday announced that it has received written agreement from the U.S. Food and Drug Administration or ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...